Skip to main content

Advertisement

Table 1 Baseline characteristics for the two groups

From: Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation

  High s-Mg Group N = 45 Low s-Mg Group N = 57 p-value
Recipient age (years) (median [IQR]) 50 [37–57] 50 [31–57] 0.551
Donor age (years) (mean ± SD) 31 ± 18 27 ± 17 0.332
Recipient gender (male) (%) 32 (71) 39 (68) 0.939
Donor gender (female) (%) 40 (100) 49 (100) 1.000
Etiology (ischemic) (%) 17 (38) 25 (44) 0.677
Recipient BMI (kg/m2) (median [IQR]) 23.7 [21.6–26.8] 23.9 [20.8–27] 0.708
Donor BMI (kg/m2) (mean ± SD) 24.6 ± 3.7 24.7 ± 2.7 0.886
Hypertension (%) 7 (16) 16 (28) 0.207
Dyslipidemia (%) 11 (24) 18 (32) 0.567
Past smoker (%) 9 (20) 15 (26) 0.609
Assist device (%) 8 (18) 7 (13) 0.646
Status 1 (%) 30 (67) 38 (67) 1.000
PRA > 30% (%) 0 (0) 1 (2) 1.000
Recipient blood type (%) 0.371
 A 17 (42) 19 (36)  
 AB 4 (10) 3 (6)  
 B 5 (13) 14 (27)  
 O 14 (35) 16 (31)  
Recipient creatinine (median [IQR]) 1.11 [1–1.3] 1 [0.9–1.2] 0.232
Recipient bilirubin (median [IQR]) 1 [0.7–1.2] 1 [0.63–1.35] 0.865
Tacrolimusa (%) 19 (42) 30 (53) 0.398
Average tacrolimusa (median [IQR]) 13 [11.4–13.8] 12.5 [10.4–13.7] 0.400
Cyclosporinea (%) 14 (31) 18 (32) 1.000
Average cyclosporinea (mean ± SD) 296 ± 56 277 ± 37 0.276
Ischemic time (min) (mean ± SD) 169 ± 46 153 ± 40 0.102
PAM (mmHg) (mean ± SD) 35 ± 12 33 ± 13 0.550
CO (mean ± SD) 3.7 ± 1.2 3.5 ± 1.2 0.362
PVR (median [IQR]) 2.2 [1.3–3] 2.3 [1.7–3.2] 0.468
CMV mismatch (%) 14 (39) 11 (33) 0.819
Statins post-HT (%) 41 (91) 53 (93) 1.000
Hypertension post-HT (%) 29 (64) 33 (58) 0.639
Average Mg in first year (mean ± SD) 2 ± 0.3 1.6 ± 0.1 < 0.001
Average Mg in first month (median [IQR]) 2 [1.9–2.2] 1.7 [1.6–1.8] < 0.001
Mg < 1.8 mg/dL in the first month (%) 3 (7) 38 (83) < 0.001
  1. SD standard deviation, BMI body mass index, PRA panel reactive antibody, PAM mean pulmonary pressure, CO cardiac output, PVR pulmonary vascular resistance, CMV cytomegalovirus, HT heart transplantation
  2. aDuring first 3 months from HT